Bottom line
Is AGNG a good fund? The bottom line
AGNG is an actively managed global stock ETF from Global X.
It charges 0.5% — about $50 a year on every $10,000 invested, cheaper than 89% of global stock funds we track.
It returned +19.7% over one year, +5.9% a year over five years (as of Dec 31, 2025, per its prospectus).
With $81.8 million in net assets and 84 holdings, its largest position is Novo Nordisk A/s (3.8%) and the top 10 make up 32.1% of the portfolio.
What stands out
- Low cost: cheaper than 89% of global stock peers
Updated Nov 19, 2026
What AGNG invests in
"The Global X Aging Population ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Indxx Aging Population Thematic Index (""Underlying Index"")."
"The Fund invests more than 80% of its total assets in the securities of the Indxx Aging Population Thematic Index (""Underlying Index""). The Fund's 80% investment policy is non-fundamental and requires 60 days prior written notice to shareholders before it can be changed. The Underlying Index is designed to provide exposure to exchange-listed companies in developed markets that facilitate the demographic trend of longer average life spans and the aging of the global population, including but not limited to companies involved in biotechnology, medical devices, pharmaceuticals, senior living facilities and specialized health care services (collectively, ""Aging Population Companies""), as defined by Indxx, LLC, the provider of the Underlying Index (""Index Provider""). The eligible universe of the Underlying Index includes the most liquid and investable companies in accordance with the…
From the fund's prospectus (filed Mar 27, 2026).
AGNG performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| AGNG | +19.7% | +5.9% | — |
| Global Stock median | +15.2% | +7.6% | +9.5% |
Source: Fund prospectus, as of Dec 31, 2025
What AGNG costs
On a $10,000 investment, AGNG's 0.5% expense ratio costs about $50 a year. The prospectus estimates $628 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.
AGNG top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Novo Nordisk A/s | 3.80% |
| 2 | Eli Lilly And Company | 3.58% |
| 3 | Edwards Lifesciences Corporation | 3.37% |
| 4 | Roche Holding AG | 3.21% |
| 5 | Abbvie Inc. | 3.16% |
| 6 | Welltower Inc. | 3.07% |
| 7 | Ventas, Inc. | 3.06% |
| 8 | Merck & Co., Inc. | 2.99% |
| 9 | Bristol-myers Squibb Company | 2.98% |
| 10 | Amgen Inc. | 2.93% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 32.1% of the fund. See all top 25 holdings and asset mix →